Omacetaxine: The FDA Decision

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 1, 2011, Pages 57-58

  Berman, Ellin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB;

ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; PNEUMONIA; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; UNITED STATES;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HARRINGTONINES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79951479887     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. ClinicalTrials.gov. Homoharringtonine (omacetaxine mepesuccinate) in treating patients with chronic myeloid leukemia (CML) with the T315I BCR-ABL gene mutation. http://clinicaltrials.gov/ct2/show/NCT00375219?term=cml-202&rank=2. December 21, 2010. ClinicalTrials.gov Identifier: NCT00375219.
2. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301-304.